Australia wants greater control over device ads
This article was originally published in Clinica
The Australian Therapeutic Goods Administration is inviting feedback on expanded proposals to change its current framework on advertising therapeutic goods to the general public.
You may also be interested in...
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
The Australian health care products regulator is inviting feedback on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices.
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.